Phase II study of docetaxel in inoperable advanced non small cell lung cancer;Etude de phase II: Docetaxel dans les cancers bronchopulmonaires non a petites cellules inoperables

Bulletin du Cancer

Volumn 87, Issue 3, 2000, Pages 253-258

  Robinet, Gilles ^a   Thomas, Pascal ^b   Pérol, Maurice ^c   Vergnenegre, Alain ^d   Lena, Hervé ^e   Taytard, André ^f   Paillotin, Dominique ^g   Bessa, El Hadi ^h   Schuller Lebeau, Marie Pascale ^h  

^a CHU MORVAN   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c CROIX ROUSSE HOSPITAL   (France)

^d Hopital du Cluzeau   (France)

^e PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^f Service de Pneumologie B   (France)

^g Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^h SANOFI   (France)

Author keywords

Docetaxel; First line chemotherapy; Monochemotherapy; Non small cell lung cancer

Indexed keywords

DIOSMIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PREDNISOLONE; TOPOTECAN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0034152250     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, et al. Polychemotherapy in advanced non-small-cell lung cancer : a meta-analysis. Lancet 1993 ; 342 : 19-21.
2. Alberti V, Anderson G, Bartolucci A, Bell D, Villalba JB, Brodin O, et al. Chemotherapy in non-small-cell lung cancer : a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-Small Cell Lung Cancer Collaborative Group. Br Med J 1995 ; 311 : 899-909.
3. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 1993 ; 11 : 1391-402.
4. Denis JN, Greene AE. A highly efficient, practical approach to natural Taxol®. J Am Chem Soc 1988 ; 110 : 5917-9.
5. Mangatal L, Adeline MT, Guenard D, Gueritte-Voegelein F, Potier P. Application of the vicinal oxyamination reaction with asymmetric induction to hemisynthesis of taxol analogues. Tetrahedron 1989 ; 45 : 4177-90.
6. Rhône-Poulenc-Rorer. Investigator's Brochure RP56976. Antony, France, International Registration Department, 1992.
7. Banerjee S, Brown DI, Fallis AG, Tomiak E, Stewart DJ. Effects of Taxotere® on two human cancer cell lines. Proc Am Assoc Cancer Res 1997 ; 38 : A 1541.
8. Fromes Y, Gounon P, Veitia R, Bissery MC, Fellous A. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem 1996 ; 15 : 377-88.
9. Andreu JM, Diaz JF, Gil R, de Pereda JM, Garcia de Lacoba M, Peyrot V, et al. Solution structure of Taxotere®-induced microtubules to 3-nm resolution. The change in protofilament number is linked to the binding of Taxol® side chain. J Biol Chem 1994 ; 269 : 31785-92.
10. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol® and Taxotere® : reversibility, ligand stoichiometry, and competition. Biochemistry 1993 ; 32 : 2747-55.
11. Peyrot V, Briand C, Diaz JF, Andreu JM. Biophysical characterization of the assembly of purified tubulin induced by Taxol® and Taxotere® (RP 56976). Cell Pharmacol 1992 ; 1 (suppl. 1) : S 118.
12. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of Taxol® analogues and their antimitotic activity. J Med Chem 1991 ; 34 : 992-8.
13. Burris HA, Eckardt J, Fields S, Rodriguez G, Smith L, Thurman A, et al. Phase II trials of Taxotere® in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1993 ; 12 : A 1116.
14. Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, Van Meerbeck J, et al. Docetaxel (Taxotere®) is active in non-small cell lung cancer (NSCLC) : a phase II trial of the Early Clinical Trials Group (ECTG). Br J Cancer 1994 ; 70 : 384-7.
15. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem JP, Woolley, et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 1994 ; 12 : 1232-7.
16. Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994 ; 12 : 1238-44.
17. Webb A, O'Brien ME. Where to go with new expensive treatments in NSCLC. Br J Cancer 1998 ; 78 : 159-62.
18. Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated non-small cell lung cancer. J Clin Oncol 1996 ; 14 : 1649-55.
19. 2 dose of docetaxel with prednisolone premedication for patients with non-small cell lung cancer. Cancer 1995 ; 75 : 968-72.
20. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, et al. Phase II study of Taxol® in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993 ; 85 : 384-8.
21. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of Taxol®, merbarone and piroxantrone in stage IV non-small cell lung cancer. The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993 ; 85 : 388-94.
22. Gatzemeier U, Heckmayer M, Neuhauss R, Schluter I, von Pawel J, Wagner H, et al. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel : a phase II trial. Semin Oncol 1995 ; 22 (6 suppl. 15) : 24-8.
23. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer : a phase II study. J Clin Oncol 1994 ; 12 : 1821-6.
24. Fossella FV, Lippman SM, Tarassoff P, Shin DM, Calayag M, Lee JS, et al. Phase I/II study of gemcitabine, an active agent for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995 ; 14 : 371 (A 1144).
25. Begbie SD, Hui R, Levi JA, Wheeler HR, Millward M, Bell DR. Initial experience with gemcitabine for non-small cell lung cancer (NSCLC) in Australia. Proc Am Soc Clin Oncol 1995 ; 14 : 378 (A 1172).
26. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer : a phase II study. J Clin Oncol 1994 ; 12 : 1535-40.
27. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al. Activity of gemcitabine in patients with non-small cell lung cancer : a multicentre, extended phase II study. Eur J Cancer 1996 ; 32A : 243-8.
28. O'Rourke M, Crawford J, Schiller J, Laufman L, Yanovich S, Ozer H, et al. Survival advantage for patients with stage IV NSCLC treated with single-agent navelbine in randomized controlled trial. Proc Am Soc Clin Oncol 1993 ; 12 : A 1148.
29. Depierre A, Lemarie A, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of navelbine (vinorelhine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991 ; 14 : 115-9.
30. Le Chevalier T, Brisgand D, Douilard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine also in advanced non-small cell lung cancer : results of a European multicenter trial including 612 patients. J Clin Oncol 1994 ; 12 : 360-7.
31. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992 ; 10 : 16-20.
32. Douillard JY, Ibrahim N, Riviere A, Spaeth D, Chomy P, Soussan K, et al. Phase II study of CPT-11 (irinotecan)in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995 ; 14 : A 1118.
33. Baker L, Khan R, Lynch T, Saravaj N, Sandler A, Feun L, et al. Phase II study of irinotecan (CPT-11) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1997 ; 16 : A 1658.
34. Pérol M, Guérin JC, Thomas P, Poirier R, Carles P, Robinet G, et al. Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non small-cell lung cancer. Lung Cancer 1996 ; 14 : 119-34.
35. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced non small-cell lung carcinoma : a meta-analysis of response, toxicity, and survival. Cancer 1998 ; 82 : 116-26.